Findings from a new study published in The Journal of Pediatrics revealed that the rate of new pediatric melanoma cases decreased between 2004 and 2010 in the United States.
A research team from University Hospitals (UH) Case Medical Center in Cleveland and the Case Western Reserve University led by Laura B. Campbell, MD, used the Surveillance, Epidemiology, and End Results cancer registries to identify new pediatric melanoma cases between 2000 and 2010.
n the last several years, targeted therapies, drugs that directly impact specific genes and proteins involved in the progression of cancer, have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy. Understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
A range of novel combinations of immunotherapies and targeted agents, including treatment triplets, will likely be part of the future paradigm of melanoma therapy as drug discovery in the field continues at a rapid pace, according to Jeffrey S. Weber, MD, PhD.
A research group at the University Clinic of Dermatology at the MedUni Vienna is on the trail of melanoma resistances to cancer drugs. The identification of the mechanisms leading to resistance to BRAF inhibitors in metastasizing melanomas harbouring the V600E BRAF mutation is a success, which may result in more effective treatments in future.
